Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

Dostarlimab is under clinical development by GSK and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

Evalstotug is under clinical development by BioAtla and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain ...

San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...

These include peptic ulcers, acute and atrophic gastritis, intestinal metaplasia, gastric adenocarcinoma and gastric B-cell lymphoma. Various bacterial virulence factors are associated with the ...

Based on previous studies, exosomes in gastric adenocarcinoma serve as biomarkers, potential therapeutic targets, and post-resistance treatment, which represents current hotspots and emerging ...